Navigation Links
Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders
Date:5/12/2009

JENA, Germany, May 12 /PRNewswire/ -- Occlutech, the leading European developer of septum occluders, today announced that it has obtained CE mark approval for its new generation ASD and PFO occluders, the Figulla Flex.

The Figulla Flex ASD and PFO occluders encompass a new innovative delivery system, making the use of a threaded hub unnecessary. The implantation of the occluder is facilitated by the ability of the delivery system to allow a 45 degree angle before release.

The Occlutech Figulla Flex will be exhibited and demonstrated at the PCR vascular intervention meeting in Barcelona from May 19th to May 22nd.

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

    Contact:

    Tor Peters
    info@occlutech.de
    Tel: +49-3641-67-51-29

    Katrin Biedermann
    katrin.biedermann@occlutech.de
    Tel.: +49-3641-67-51-20


'/>"/>
SOURCE Occlutech GmbH
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
2. AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH
3. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
4. Hard To Treat Diseases (HTDS) Obtains HAS Certificate
5. American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product
6. High dosage brachytherapy obtains excellent results in head and neck tumors
7. China Sky One Medical, Inc. Obtains SFDA Approval for Policresulen Vaginal Suppositories
8. Cynosure Obtains Favorable Markman Rulings in Patent Infringement Case Against CoolTouch
9. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
10. Steve Teal, Santa Rosa Attorney, Obtains $850,000 for Client in Highest Hospital Negligence Verdict in Mendocino County
11. New York Attorney Obtains $2.25 Million Verdict for Client Injured on Grounds of Bronx Eye Surgery Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... ... company, today announced the launch of DonorBridge, its process and engagement analytics ... of software innovation and industry expertise with predictive analytics to help nonprofits ...
(Date:4/29/2017)... ... ... More than half of Americans suffering from noise-induced hearing loss do not ... causes hearing loss? May 1 marks the beginning of Better Hearing & Speech Month—a ... as schedule a hearing evaluation for anyone with concerns about his/her hearing. , Approximately ...
(Date:4/28/2017)... ... April 28, 2017 , ... It's not always common knowledge ... of illnesses that are unclear as to whether or not they are contagious, and ... one of these illnesses. So, FindaTopDoc took a look into the matter. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced ... test throughout the Northeast U.S. , GlycoMark is the only clinically available ... test provides a clinically proven one- to two-week measure of hyperglycemic excursions, often ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: